HLN Price Prediction Next Week
Technical Analysis
Based on the technical analysis, HLN shows a neutral to slightly bearish trend. The stock has been trading in a consolidation pattern with key support around $8.81 and resistance at $9.38 based on Fibonacci levels.
News Sentiment Analysis
Recent news indicates several significant developments:
- Barclays maintains a Buy rating with a price target of £4.15, suggesting an 8.66% upside potential
- Pfizer announced plans to sell approximately 700M ordinary shares (7.7%) of Haleon
- Morgan Stanley recently downgraded Haleon to Equal Weight from Overweight
Price Prediction for Next Week
Based on technical indicators and news sentiment:
Target Prices:
- Support: $8.81 (Fibonacci S2)
- Resistance: $9.38 (Fibonacci R1)
The stock is likely to trade between $8.81-$9.38 next week. The selling pressure from Pfizer's planned share sale could create temporary downward pressure, but strong analyst support and fundamental outlook suggest limited downside.
Trading Recommendation
SELL with a target price of $8.81. The rationale:
- Pfizer's large share sale announcement creates near-term selling pressure
- Recent downgrade from Morgan Stanley indicates shifting sentiment
- Technical indicators showing bearish momentum with RSI at 48.96 suggesting neutral to slightly bearish momentum
Set stop-loss at $9.52 (Fibonacci R2) to manage risk.
HLN Similar Chart Price Prediction
The price of HLN is predicted to go up -20.66%, based on the high correlation periods with CLLS. The similarity of these two price pattern on the periods is 97.34%.
HLN
CLLS
Down: -20.66%Similarity: 97.34%
HLN Revenue Forecast
HLN EPS Forecast
HLN FAQs
What is revenue forecast for next quarter？
HLN VS S&P500
We expect Haleon, with financial and operational independence, to bolster its portfolio through product innovation and tuck-in acquisitions and expand the strong foothold it has in the consumer self-care industry.
Haleon is well positioned to enjoy long-term macro trends including aging population, premiumization of consumer healthcare, and growing emerging markets.
Haleon can utilize its large salesforce and distribution network to continue rolling out brands in new markets and use its expertise to increase household penetration and build up market share.
HLN Analyst's Forecast
Rashad Kawan
Morgan Stanley
Buy
Price Target
$9.9 → $11
Upside
+4.19%
Morgan Stanley raised the firm's price target on Haleon to $10.95 from $9.90 and keeps an Overweight rating on the shares. The firm also removed the shares as a Top Pick. As one of the best-performing stocks in European staples year-to-date, Haleon offers less absolute upside from here, the analyst tells investors in a research note. However, the firm continue to favors the company relative to other food alternatives.